Body

Medicare

Medicare is a government-funded program that gives healthcare coverage to people 65 or older.

People under 65 may be eligible for Medicare if they have:

  • Certain disabilities
  • End-stage renal disease (ESRD)
  • Amyotrophic Lateral Sclerosis (ALS), also called Lou Gehrig’s disease

There are 4 parts of Medicare: A, B, C, and D.

Medicare can be confusing. In this video we break down the different parts of Medicare, what they are for, and what you need to know.

 

Part A

Hospital Insurance

Inpatient care in hospitals and skilled nursing facilities; hospice care, and some home health care

Part B

Medical Insurance

Doctor visits and other outpatient services; medications given by a healthcare provider

Part C

Medicare Advantage

Part A and Part B offered by private health plans; most plans include prescription drug coverage

Part D

Prescription drug coverage

Helps cover the cost of prescription medications and some recommended vaccines

While Medicare covers many healthcare needs, it may not cover all healthcare costs for everyone. You may have to pay a monthly premium for Medicare and a co-pay, co-insurance, or deductible.

Janssen CarePath can help you learn how Medicare may cover your Janssen medications. We can also give you information on cost support.

Medicare Resource Guide
Medicare Resource Guide
Medicare Resource Guide

Medicare Resource Guide

Medicare Resource Guide (en español)

Learn about the different parts of Medicare. Also see what it may cover, including medications.

Back

IMPORTANT SAFETY INFORMATION
  • Minimize
  • Expand
  • Full Screen
  • Return to Website

What is RYBREVANT® (amivantamab-vmjw)?

RYBREVANT® is a prescription medicine used to treat adults:

  • in combination with carboplatin and pemetrexed as a first-line treatment for non-small cell lung cancer (NSCLC) that:
    • has spread to other parts of the body (metastatic) or cannot be removed by surgery, and
    • has a certain abnormal epidermal growth factor receptor “EGFR” gene(s)
  • alone for the treatment of non-small cell lung cancer (NSCLC) that:
    • has spread to other parts of the body (metastatic) or cannot be removed by surgery, and
    • has a certain abnormal EGFR gene(s), and whose disease has worsened on or after platinum-based chemotherapy.

Your healthcare provider will perform a test to make sure that RYBREVANT® is right for you. It is not known if RYBREVANT® is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Before you receive RYBREVANT®, tell your healthcare provider about all of your medical conditions, including if you:

  • have a history of lung or breathing problems.
  • are pregnant or plan to become pregnant. RYBREVANT® can harm your unborn baby.

Females who are able to become pregnant:

  • Your healthcare provider should do a pregnancy test before you start treatment with RYBREVANT®.
  • You should use effective birth control (contraception) during treatment and for 3 months after your final dose of RYBREVANT®.
  • Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with RYBREVANT®.
  • are breastfeeding or plan to breastfeed. It is not known if RYBREVANT® passes into your breast milk. Do not breastfeed during treatment and for 3 months after your final dose of RYBREVANT®.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive RYBREVANT®?

  • RYBREVANT® will be given to you by your healthcare provider by intravenous infusion into your vein.
  • Your healthcare provider will decide the time between doses as well as how many treatments you will receive.
  • Your healthcare provider will give you medicines before each dose of RYBREVANT® to help reduce the risk of infusion-related reactions.
  • RYBREVANT® may be given in combination with the medicines carboplatin and pemetrexed. If you have any questions about these medicines, ask your healthcare provider.
  • If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

What should I avoid while receiving RYBREVANT®?

RYBREVANT® can cause skin reactions. You should limit your time in the sun during and for 2 months after your treatment with RYBREVANT®. Wear protective clothing and use sunscreen during treatment with RYBREVANT®.

What are the possible side effects of RYBREVANT®?

RYBREVANT® may cause serious side effects, including:

  • infusion-related reactions. Infusion-related reactions are common with RYBREVANT® and can be severe or serious. Tell your healthcare provider right away if you get any of the following symptoms during your infusion of RYBREVANT®:
  • shortness of breath
  • fever
  • chills
  • nausea
  • flushing
  • chest discomfort
  • lightheadedness
  • vomiting
  • lung problems. RYBREVANT® may cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you get any new or worsening lung symptoms, including shortness of breath, cough, or fever.
  • skin problems. RYBREVANT® may cause rash, itching, and dry skin. You may use alcohol-free moisturizing cream for dry skin. Tell your healthcare provider right away if you get any skin reactions. Your healthcare provider may treat you with a medicine(s) or send you to see a skin specialist (dermatologist) if you get skin reactions during treatment with RYBREVANT®. See “What should I avoid while receiving RYBREVANT®?”
  • eye problems. RYBREVANT® may cause eye problems. Tell your healthcare provider right away if you get symptoms of eye problems which may include:
  • eye pain
  • dry eyes
  • eye redness
  • blurred vision
  • changes in vision
  • itchy eyes
  • excessive tearing
  • sensitivity to light

Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get eye problems during treatment with RYBREVANT®. You should not use contact lenses until your eye symptoms are checked by a healthcare provider.

The most common side effects of RYBREVANT® in combination with carboplatin and pemetrexed include:

  • rash
  • infected skin around the nail
  • sores in the mouth
  • infusion-related reactions
  • feeling very tired
  • swelling of hands, ankles, feet, face, or all of your body
  • constipation
  • decreased appetite
  • nausea
  • COVID-19
  • diarrhea
  • vomiting
  • changes in certain blood tests

The most common side effects of RYBREVANT® when given alone:

  • rash
  • infusion-related reactions
  • infected skin around the nail
  • muscle and joint pain
  • shortness of breath
  • nausea
  • feeling very tired
  • swelling of hands, ankles, feet, face, or all of your body
  • sores in the mouth
  • cough
  • constipation
  • vomiting
  • changes in certain blood tests

Your healthcare provider may temporarily stop, decrease your dose, or completely stop your treatment with RYBREVANT® if you have serious side effects.

These are not all of the possible side effects of RYBREVANT®.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA‑1088.

General information about the safe and effective use of RYBREVANT®:

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for information about RYBREVANT® that is written for health professionals.

Please read full Prescribing Information for RYBREVANT®.

cp-213277v4